566C80, an antimalarial hydroxynaphthoquinone with broad spectrum: experimental activity against opportunistic parasitic infections of AIDS patients.
Hydroxynaphthoquinone 566C80 was synthesised and initially developed as an antimalarial with potent activity against drug-resistant strains of the human malaria parasite, Plasmodium falciparum. Subsequent studies have revealed that in addition, this compound has experimental activity, both in vitro and in vivo, against Pneumocystis carinii and Toxoplasma gondii; the data obtained thus far for Cryptosporidium parvum are equivocal. Currently 566C80 is being assessed clinically not only against malaria, but also against P. carinii pneumonia, toxoplasmosis and cryptosporidiosis.
Gutteridge
W E
WE
Wellcome Research Laboratories, Beckenham, Kent, England.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000818:Animals; D000962:Antimalarials / Q000737:chemistry / Q000627:therapeutic use*; D053626:Atovaquone; D003457:Cryptosporidiosis / Q000150:complications / Q000188:drug therapy; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015394:Molecular Structure; D009285:Naphthoquinones / Q000737:chemistry / Q000627:therapeutic use*; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D011010:Pneumocystis / Q000187:drug effects; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy; D051381:Rats; D013329:Structure-Activity Relationship; D014123:Toxoplasmosis / Q000150:complications / Q000188:drug therapy
D000962:Antimalarials; D009285:Naphthoquinones; D053626:Atovaquone